Goods & Services

Immunoassay reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use; diagnostic substances for medical use; reagents for blood grouping [for medical purposes].

Goods & Services

Immunoassay reagents for medical use, diagnostic agents for medical use, diagnostic reagents for medical use, diagnostic substances for medical use, Reagents for blood grouping [for medical purposes

Goods & Services

Immunoassay reagents for medical use, Diagnostic preparations for medical purposes, Diagnostic reagents for medical use, Diagnostic substances for medical use, Reagents for blood grouping [for medical purposes]. Immunodetection services for medical purposes.

Goods & Services

Immunoassay reagents for medical use, Serums for medical purposes, Reagents for medical use, Diagnostic preparations for medical purposes, Diagnostic reagents for medical use, Biochemical preparations for medical use, Biological reagents for medical use, Diagnostic substances for medical use, Reagents for blood grouping [for medical purposes]. Immunodetection services for medical purposes.

Abstract

Tissue for use as a transplant, which tissue is allogeneic or xenogeneic and respectively the tissue may express an MHC I molecule that is immunologically incompatible to the transplant recipient and/or may express an MHC II molecule immunologically incompatible to the transplant recipient. The tissue suitable for use as a transplant and the method for its production include a genetic alteration of the tissue that provides for immunologic compatibility of the tissue with a transplant recipient. In the tissue for use as a transplant, which tissue expresses allogeneic or xenogeneic MHC I and/or allogeneic or xenogeneic MHC II molecules, the expression of the allogeneic or xenogeneic MHC I is downregulated by at least 50% to up to 90%, preferably the expression of the allogeneic or xenogeneic MHC I is downregulated by at least 60%.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Modified MHC I molecules that can be expressed in cell culture and can be more stable than natural MHC I molecules. An analytical process uses the modified MHC I molecules, e.g. for determination of antibodies in a serum sample directed against these MHC I molecules. MHC I is provided which has at least one covalent bond formed between a Cystein in the alpha chain and a Cystein in the β2-microglobulin.

IPC Classes  ?

• C07K 14/74 - Major histocompatibility complex [MHC]

Goods & Services

Biological reagents for medical use; Biotechnological preparations for medical use; Diagnostic chemical reagents for medical use; Chemical reagents for medical or veterinary purposes; Chemical reagents for medical use; Chemical test reagents [medical]; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic testing materials for medical use; Diagnostic reagents for medical use; Diagnostic substances for medical use; Albuminous preparations for medical purposes; Immunoassay reagents for medical use; In vitro diagnostic preparations for medical use; Indicators for medical diagnosis; Clinical medical reagents; Medical diagnostic test strips. Consultancy relating to biotechnology; Research relating to biotechnology; Research and development in the field of biotechnology. Medical diagnostic services.

Abstract

The invention relates to a tissue for use as a transplant, which tissue is allogeneic or xenogeneic and respectively the tissue may express an MHC I molecule that is immunologically incompatible to the transplant recipient and/or may express an MHC II molecule immunologically incompatible to the transplant recipient. The tissue suitable for use as a transplant and the method for its production comprise a genetic alteration of the tissue that provides for immunologic compatibility of the tissue with a transplant recipient. In the tissue for use as a transplant, which tissue expresses allogeneic or xenogeneic MHC I and/or allogeneic or xenogeneic MHC II molecules, the expression of the allogeneic or xenogeneic MHC I is downregulated by at least 50% to up to 90%, wherein preferably the expression of the allogeneic or xenogeneic MHC I is downregulated by at least 60%.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention provides two newly identified blood group antigens (BGA), analytical processes for identifying the presence of the nucleotide sequence encoding these BGA and analytical processes for identifying these BGA proteins and an analytical process for identifying the presence of antibody directed against these BGA in a blood serum sample. The invention provides two allelic variants of SEQ ID NO: 1, also termed DACY and YCAD. These variants have been found to be BGA, which are epitopes that are recognized by serum antibodies, the BGA, or epitopes. These epitopes have been found to be functional, e.g. found to be recognized by serum antibodies which also recognize full-length CR1 protein in soluble form, e.g. lacking the transmembrane domain, as well as natural full-length CR1 membrane- bound on RBC or RBC membrane fragments.

IPC Classes  ?

• C07K 16/34 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
• C12N 5/078 - Cells from blood or from the immune system
• G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to modified MHC I molecules that can be expressed in cell culture and can be more stable than natural MHC I molecules. Further, the invention relates to analytical processes using the modified MHC I molecules, e.g. for determination of antibodies in a serum sample directed against these MHC I molecules. The invention provides MHC I which has at least one covalent bond formed between a Cystein in the alpha chain and a Cystein in the β2-microglobulin.

IPC Classes  ?

• C07K 14/74 - Major histocompatibility complex [MHC]

Goods & Services

Biological reagents for medical use; Biotechnological preparations for medical use, namely, for genetic modification of cells, tissues and organs; Albuminous preparations for medical purposes; Clinical medical reagents for therapeutical use

Goods & Services

Biological reagents for medical use; Biotechnological preparations for medical use; Diagnostic chemical reagents for medical use; Diagnostic chemical reagents for medical use; Chemical reagents for medical or veterinary purposes; Chemical reagents for medical use; Chemical test reagents [medical]; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations; Diagnostic biomarker reagents for medical purposes; Diagnostic testing materials for medical use; Diagnostic reagents for medical use; Diagnostic substances for medical use; Albuminous preparations for medical purposes; Immunoassay reagents for medical use; In vitro diagnostic preparations for medical use; Indicators for medical diagnosis; Clinical medical reagents; Medical diagnostic test strips. Consultancy relating to biotechnology; Research relating to biotechnology; Research and development in the field of biotechnology. Medical diagnostic services.

Abstract

An analytical process for detecting antibody in human blood serum, which antibody is directed against blood group antigen, wherein the serum contains an additional antibody directed against a surface antigen, by contacting the serum to be analysed with blood cell membranes, which naturally bear surface blood group antigens, followed by detection of agglutination which indicated the presence of antibody directed against at least one surface antigen of the blood cell membranes. The agglutination reaction caused by the additional antibody is prevented, allowing the detection of anti-blood group antibody.

IPC Classes  ?

• G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
• G01N 33/555 - Red blood cell
• G01N 33/541 - Double or second antibody
• G01N 33/563 - ImmunoassayBiospecific binding assayMaterials therefor involving antibody fragments
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

An analytical process for detecting antibody in human blood serum, which antibody is directed against blood group antigen, wherein the serum contains an additional antibody directed against a surface antigen, by contacting the serum to be analysed with blood cell membranes, which naturally bear surface blood group antigens, followed by detection of agglutination which indicated the presence of antibody directed against at least one surface antigen of the blood cell membranes. The agglutination reaction caused by the additional antibody is prevented, allowing the detection of anti-blood group antibody.

IPC Classes  ?

• G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types

Abstract

An analytical process for detecting antibody in human blood serum, which antibody is directed against blood group antigen, wherein the serum contains an additional antibody directed against a surface antigen, by contacting the serum to be analysed with blood cell membranes, which naturally bear surface blood group antigens, followed by detection of agglutination which indicated the presence of antibody directed against at least one surface antigen of the blood cell membranes. The agglutination reaction caused by the additional antibody is prevented, allowing the detection of anti-blood group antibody.

IPC Classes  ?

• G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types